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ABSTRACT PI3Kδ is a lipid kinase that is believed to be important in the migration and 
activation of cells of the immune system.  Inhibition is hypothesised to provide a powerful yet 
selective immunomodulatory effect that may be beneficial for the treatment of conditions 
such as asthma or rheumatoid arthritis.  In this work we describe the identification of 
inhibitors based on a thiazolopyridone core structure and their subsequent optimisation for 
inhalation.  The initially identified compound (13) had good potency and isoform selectivity 
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but was not suitable for inhalation.  Addition of basic substituents to a region of the molecule 
pointing to solvent was tolerated (enzyme inhibition pIC50 >9) and by careful manipulation of 
the pKa and lipophilicity we were able to discover compounds (20b, 20f) with good lung 
retention and cell potency that could be taken forward to in-vivo studies where significant 
target engagement could be demonstrated. 
Introduction 
Phosphoinositide 3-kinases (PI3Ks) are a group of enzymes that are involved in the 
phosphorylation of the membrane-bound inositol phospholipids in the 3-position of the 
inositol moiety.  The eight known members are divided into three classes, I, II and III.  Class I 
PI3Ks have been the most extensively studied of these subclasses; the class is further 
subdivided into IA (PI3Kα, β & δ) and class IB (PI3Kγ) based upon the types of regulatory 
subunits with which the catalytic domains combine in the active heterodimeric forms.  Class 
1A PI3Ks mediate the signal transduction from receptor tyrosine kinases whilst PI3Kγ is 
principally activated by GPCRs.  PI3Kδ & γ are restricted to cells of the haematopoietic 
system whilst PI3Kα & β are ubiquitous.  Dysregulation of the PI3K system (the kinases and 
the associated phosphatases) is often observed in cancers and there has been a great deal of 
interest in developing pan or selective inhibitors of PI3Ks for applications in oncology.
1,2
  
Evidence is growing that inhibition of PI3Kδ and/or γ can have powerful yet selective effects 
on the immune response and inhibitors have attracted interest as potential treatments for 
diseases with a significant immunological component, such as rheumatoid arthritis and 
asthma.
3-6
  Understanding of the biology of PI3Ks is developing fast, however there are still 
details and subtleties to be worked out.  Several reviews describe the current state of 
knowledge.
7-10,
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Recently the PI3Kδ selective inhibitor idelalisib (Figure 1, A) has been launched as the first 
PI3K inhibitor to market for the treatment of B-cell cancers.
11
  The drug is effective but shows 
a number of significant side-effects.
12
 
 
BA  
Figure 1.  Reference PI3Kδ inhibitors.  
 
We were interested in PI3Kδ as a potential treatment for lung conditions such as asthma.  
We have previously described an earlier series of PI3Kδ inhibitors that we investigated but 
which showed disappointing cell potencies.
13
  We selected an inhaled approach with a view to 
minimising the systemic exposure and thus the potential for side-effects from either target-
related or off-target interactions.  This early decision to follow an inhaled approach mandated 
several aspects of our medicinal chemistry strategy: i,  The limitations on dose deliverable 
through standard inhalers meant that achieving sub-nanomolar potency was crucial. ii,  
Soluble compounds are typically cleared from the lungs in a matter of minutes
14
 whilst 
inflammatory cells are recruited to the lung continuously, so sufficient exposure and retention 
in the lung is required.  iii,  In order to minimise systemic exposure oral bioavailability should 
be low and plasma clearance high.   
Multiple chemotypes have been described as PI3Kδ selective inhibitors.15  Broadly 
speaking they fall into two categories, “propeller” shaped compounds, such as idelalisib, that 
access an induced pocket
16
 and other chemotypes that all appear to derive selectivity by a 
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combination of optimising the interactions in the affinity pocket for PI3Kδ and accessing the 
“tryptophan shelf”. The “tryptophan shelf” describes the face of Tyr760 (PI3Kδ numbering) 
which is accessible in PI3Kδ owing to the small size of Thr750, whereas larger residues in the 
corresponding positions of PI3Kα, β and γ occlude this surface.17 
Since the disclosure of the structure of IC87114
18
 (Figure 1, B) in 2003 there has been 
extensive medicinal chemistry exploration of chemotypes that can give “propeller” type 
structures.
15
  We started our search for PI3Kδ inhibitors by looking for a novel propeller-
shaped chemotype in view of the heavy patenting around 6,6-fused systems such as 
isoquinolinones and quinazolinones.  We identified the thiazolopyridone ring system as a 
potentially suitable core for our explorations.  Since the completion of the work described 
herein but prior to the submission of this article the same core has been described in the patent 
literature for some PI3Kδ inhibitors.19 
Chemistry 
Synthesis of the compounds described in this paper followed a general route with late-stage 
diversification in order to introduce changes to the aryl substituents.  The route (Scheme 1) 
started by following the procedures described by the Almqvist group for the synthesis of 6-
bromothiazolidinopyridones.
20,21
  Initially we used a racemic synthesis with late-stage chiral 
separation but the majority of work was carried out starting with chiral (R)-2-chloropropionic 
acid.  Coupling of this acid with Meldrum’s acid gave dioxinone 3.  This dioxinone reacted 
thermally with thiazoline 2 to give the core ring system 4 as a mixture of diastereomers.  Ring 
bromination of 4 was followed by sulfoxidation, Pummerer rearrangement and elimination to 
deliver the aromatised compound 7.  Displacement of the chlorine with sodium azide 
followed by reduction gave amine 9.  CBZ protection of the free amine produced carbamate 
10. 
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Suzuki coupling of racemic 10 from the initial synthesis with phenyl boronic acid gave 11 
that was deprotected to amine 12 which on heating with 4-amino-6-chloropyrimidine-5-
carbonitrile, followed by separation of the enantiomers by chiral HPLC produced initial lead 
13 (Scheme 2).   
Chiral analysis of 10 produced using (R)-2-chloropropionic acid showed that some loss of 
stereochemical purity had occurred during the synthesis.  10 however proved to be suitable for 
chiral SFC and could be purified to >99% enantiopurity.  Cleavage of the carbamate returned 
chirally pure amine 9 that was used as the starting point for subsequent exploration (Scheme 
3).  Heating amine 9 and 4-amino-6-chloropyrimidine-5-carbonitrile in n-butanol gave the 
bromide 14 that was coupled with substituted phenyl boronic acids to give, after deprotections 
and, where required, reductive amination, compounds 15a and 17-19.  Alternatively use of an 
aldehyde functionalised boronic acid gave intermediate 16 that could be reductively aminated 
with a range of amines to give, in some cases after additional manipulation, compounds 15b-g 
and 20a-l. 
 
1
viii
  8 X = N
3
 
  9 X = NH
2
10 X = NCbz
ix
7 
2
v
3
4
vi
5
6
i
vii
ii
iii iv
 
Scheme 1. 
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i, Lawesson’s reagent, THF, 65 ºC   ii, Meldrum’s acid, DCC, DMAP, CH2Cl2   iii, TFA, 
TFAA, ClCH2CH2Cl   iv, isoamyl nitrite, HBr (40% aq), CH2Cl2, <-5 °C   v, mCPBA, 
CH2Cl2, 0 °C   vi, TFAA, PhMe, 60 °C then cH2SO4, CH2Cl2, 0 °C - RT   vii, NaN3, DMF, 
45 ºC   viii, Ph3P, CH2Cl2, reflux   ix, CbzCl, K2CO3, THF: water 10:1, 0 °C    
 
10  X = Br 
11  X = Ph
12 13
iiiii
i
 
Scheme 2. 
i PhB(OH)2, PdCl2(dppf).CH2Cl2, DME-water , 100 ºC   ii, BBr3, CH2Cl2, 0 °C - RT   iii, 4-
amino-6-chloropyrimidine-5-carbonitrile , DIEA, n-butanol, 120 ºC then Chiral HPLC    
 
20h-j 
ix
10 9
14
18 1916
15b-g; 20a-g
iii
 x
15a 17
20k,l
iviii
v
vi vii viii
R2 = H R1 = (CH2)3C(OEt)2
R2 = Me
15 - 20
 
Scheme 3. 
i, BBr3, CH2Cl2, 0 °C - RT   ii, 4-amino-6-chloropyrimidine-5-carbonitrile , DIEA, n-
butanol, 120 °C   iii, ArB(OH)2, PdCl2(dppf).CH2Cl2, Cs2CO3, DME-water, 100 ºC  then 
TFA, CH2Cl2   iv, ArB(OH)2 PdCl2(dppf).CH2Cl2, Cs2CO3, DME-water, 100 ºC   v HNRR, 
NaBH3CN, MeOH-CH2Cl2   vi, a) ArB(pinacol), 3
rd
 generation Pd precatalyst, P(Cy)3.HBF4, 
K3PO4, dioxan-water, 130 °C b) TFA, CH2Cl2 c) CH2O, NaBH3CN, AcOH, MeOH   vii, 
ArB(pinacol), 3
rd
 generation Pd precatalyst, P(Cy)3.HBF4, K3PO4, dioxan-water, 130 ºC then 
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DEAD, Me2NCH2CH2OH, Ph3P, THF, 0 ºC   viii, a) ArB(pinacol), Pd dppf, Cs2CO3, dioxan-
water, 130 ºC b)  TFA, CH2Cl2  c)  acetone, NaBH3CN, AcOH, CH2Cl2-MeOH   ix, 
NaBH3CN, acetaldehyde or CH2O, AcOH, CH2Cl2-MeOH   x, a) CH2O, NaBH3CN, AcOH, 
MeOH  b) TFA / CH2Cl2-water  c) amine, NaBH3CN, AcOH, CH2Cl2-MeOH  
 
Results and discussion 
Initial thiazolopyridone 13 met our criteria for a lead with excellent PI3Kδ potency in both 
biochemical and cellular assays, very good selectivity against PI3Kα and acceptable 
selectivity against PI3Kβ and γ (Table 1).   
 
Table 1.  SAR of m-benzylamines. 
Compound 
 
R 
 
PI3K pIC50 Solubility 
μM 
LogD 
 δ α β γ δ cell 
13 H 9.4 6.2 7.3 7.9 9.2 77 2.7 
15a CH2NH2 9.2 5.9 8.1 6.7 7.4 >1000 -0.3 
15b CH2NHMe 9.1 5.9 8.0 6.2 7.7 >1000 -0.2 
15c CH2NMe2 9.1 5.5 7.2 6.2 8.8 956 0.8 
15d 
CH2NHCH2CH2O
Me 9.2 5.9 7.7 6.4 8.6 >1000 0.7 
15e 
CH2N(Me)CH2CH(
Me)2 
9.3 5.7 7.0 <6.1 9.2 12 2.3 
15f N*
 
9.3 5.8 7.4 6.3 8.6 954 0.5 
15g 
CH2NH(CH2)4O(C
H2)2Ph 
9.4 6.3 8.1 6.5 8.9 699 2.3 
All biological values are mean of ≥ 3 replicates 
 
As a model for inhalation we dosed compounds by intra tracheal (i.t.) administration of a 
solution of compound to rats followed by termination at time-points up to 24 h and 
subsequent analysis of the residual compound in the lungs.  Compound 13, a moderately 
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soluble (77 μM) neutral molecule, was cleared extremely rapidly from lung; compound could 
only be detected at the first time-point (3 minutes after dosing, table 2).  Given the rapid 
clearance from the lung of the parent compound we needed to find a mechanism by which we 
could obtain duration.  Two main strategies have been described to produce a prolonged effect 
in lung tissue: low solubility
22,23
 or basicity.
24
  Solubility-driven approaches require that 
material dissolves slowly over the time after dosing to produce the effect whilst a pH-driven 
approach relies on dissolved compound being trapped in acidic organelles, such as lysosomes, 
which are prevalent in lung tissue, to provide a depot that is then released slowly over an 
extended period of time.  We prioritised the addition of basic centres as a potentially 
predictable method to modulate lung retention.   
Crystallisation of 13 in a murine PI3Kδ construct (Figure 2) showed that the compound 
bound in a similar conformation and into the same induced pocket in the enzyme that has 
been described previously.
16
  Examination of the crystal structure revealed that there might be 
scope to extend from the meta position of the phenyl ring towards solvent if the phenyl ring 
made a small rotation, enabling modulation of the physical properties of the compounds 
without affecting the enzyme affinity.   
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Figure 2.  Compound 13 bound in murine PI3Kd showing the ATP binding pocket with the 
induced pocket between Trp760 and Met752 and with hydrogen bonds to the NH of Val828 
and the carbonyl of Glu826 making the hinge interaction.  
 
Table 2.  Lung PK of compounds 13, 15a-g. 
Compound Lung 
t½ 
h 
Residual 
dose at 4 h 
(%) 
Residual  
dose at  
24 h (%) 
13 NA* 0 0 
15a 1.6 2 0 
15b 4.9 2.5 0 
15c 2.3 0.2 0 
15d 1.3 0.8 0 
15e NA* 0 0 
15f 1.1 0.5 0 
15g 3.5 4.8 0 
All time-points were a mean from 3 animals 
* Compounds 13 & 15e were only detected in lung tissue at the first time-point of the 
experiment (3 minutes after dosing) and then only 2 % and 6.5 % of the total dose 
respectively. 
 
Addition of a benzylic amine to the meta position of the pendant phenyl in 13 gave 
compounds (15a, b, c) that retained the PI3Kδ potency of 13 but exhibited differing 
selectivities towards the other isoforms. (Table 1)  Addition of the basic centre increased 
selectivity towards PI3Kγ by reducing potency at that isoform, particularly for 15b & c, thus 
increasing selectivity.  Selectivity towards PI3Kβ on the other hand was reduced for 15a & b, 
though not for 15c.  Selectivity against PI3Kα was slightly increased, with 15c again the most 
selective.  All three compounds had low lipophilicity, particularly 15a & b, and these two 
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showed a significant potency drop-off in the cell assay, probably reflecting poor cell 
permeability. 
Crystallisation of 15c with PI3Kδ (Figure 3) showed an almost complete superposition with 
the structure of 13 without rotation of the phenyl ring; the dimethylamino group, as expected, 
pointed into the solvent channel.  The dimethylamino group lies in the proximity of Asn836 
(PI3Kδ), the amide moiety of which can be seen to rotate slightly to accommodate the ligand; 
this is one of the few highly variable residues in the vicinity of the ATP binding site of the 
highly homologous PI3K isoforms.  The corresponding residues in the other isoforms PI3Kα 
Gln859, PI3Kβ Asp856 and PI3Kγ Lys890 are all different.  These differences can in part 
explain the observed selectivity changes, thus the positively charged protonated amines can 
make a favourable interaction with the aspartate anion of PI3Kβ that is reflected in the 
increased potency at this isoform, but make an unfavourable one with the cation of Lys890 in 
PI3Kγ accounting for the big drop in potency observed.  The neutral glutamine in PI3Kα has a 
more modest effect, but is a larger group than the asparagine in δ and thus the slight loss of 
potency as the size of the substituent increases from 15a to b to c can be understood.  These 
effects were seen consistently for further examples (15d–f) and consequently we shifted our 
focus to tertiary amines in this position to ensure we obtained sufficient selectivity vs. PI3Kβ. 
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Figure 3.  View of 15c (grey) overlayed with 13 (blue) showing the very similar 
conformations adopted by the ligands and the almost identical protein conformations.  Note 
the movement of the sidechain amide of Asn836 permitting the dimethylamino group to be 
accommodated. 
 
Larger N-substituents were tolerated, as expected based on this group pointing to solvent 
(Figure 4), and enzyme affinities at all four isoforms were remarkably consistent across the 
series 15a-g, barring the effect already mentioned with PI3Kβ.  More lipophilic compounds 
however showed improved cell potencies, consistent with a potential favourable effect on 
membrane permeability (Table 1, Figure 5). We investigated the preferred location of the 
basic centre by making a series of changes to the linker length between the amine and the 
aromatic ring (17, 18, 19, Table 3).  As the distance between the amine and the aromatic ring 
increased beyond two atoms the potency at PI3Kβ reduced, consistent with loss of a 
favourable interaction with Asp856; activity against the other isoforms was little changed.  
Once again cell potency dropped off for compounds with low LogD. 
 
 
Figure 4.  Docked structure of 20f (grey) overlaid with 13 (blue) in murine PI3K showing 
the large substituted aminopiperidine accommodated in the solvent channel. 
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Figure 5.  Enzyme and cell potencies for compounds 13, 15a-g, 17, 18, 19 showing cell 
drop-off at low lipophilicity. 
 
Table 3.  SAR of alternate positions for the base. 
15c, 17-19  
Compound R 
PI3Kδ 
pIC50 
PI3Kα 
pIC50 
PI3Kβ 
pIC50 
PI3Kγ 
pIC50 
PI3Kδ 
cell 
pIC50 
Log
D 
15c CH2NMe2 9.1 5.5 7.2 6.2 8.8 0.8 
17 CH2CH2NMe2  9.1
†
  5.9
†
  7.3
†
 <6.0
†
  8.6
‡
 0.5 
18 OCH2CH2NMe2 8.8 5.1 6.7 6.5 8.2 0.7 
19 N
*
 
9.2 6.0 6.4 6.6 8.8 1.1 
All biological values are means of ≥ 3 replicates except † n= 1and ‡ n = 2 
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In contrast to compound 13, i.t. dosing of 15a-g to rat lung showed measureable half-lives 
for all except 15e, but the vast majority of compound was still cleared within a short period 
and negligible compound was present 24 h after dosing for any of the compounds. (Table 2)  
We focussed on the amount of compound retained at 4 and 24 h to guide our design rather 
than the half-life as the latter reflected the terminal β-phase only and did not account for 
differences in the amount of compound lost in the rapid initial α-phase, which was often 
>99% (Figure 5).  Compounds 15e and g both met the criteria of Austin et al
25
 for obtaining 
duration with inhaled β-agonists (pKa > 8, LogD > 2; pKa could not be determined for 15e 
but related tertiary benzylamines had pKa > 9; pKa 15g = 9.4).  The long phenylethoxyalkyl 
chain of 15g was modelled on that used for β-agonists like Salmeterol and Sibenadet.26  
Despite these precedents 15e was barely retained at all in lung whilst 15g, though having the 
greatest retention of this group of compounds, still exhibited insufficient lung residence for 
our purposes.   
In parallel with our investigations of basic sidechains we sought to investigate dibasic 
analogues. (Table 4)  The first two compounds synthesised (20a, b) were highly potent PI3Kδ 
inhibitors.  As with the monobases the secondary amine 20a was less selective against PI3Kβ 
then the tertiary amine 20b.  Both compounds showed reduced cell potency, consistent with 
their low lipophilicities.  When dosed IT to rats 20b, but not 20a, showed excellent lung 
retention with both a long half-life and a substantial proportion of the dose remaining in the 
lung 24 h after dosing (table 4, Figure 6).  For 20b there was still an initial α-phase with a 
rapid decrease of compound over the first 30 minutes, followed by a prolonged β-phase where 
the levels declined slowly however dibase 20b exhibited the base-driven PK profile that we 
were seeking for our compounds. 
 
Table 4.  Data for dibasic compounds 20a-l.  
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20a-l  
20a
20d
20k
20e
20b 20f
20c
20j
20h
20i
20g
20l
 
Compound 
PI3Kδ 
pIC50 
PI3Kβ 
pIC50 
PI3Kδ 
cell 
pIC50 
LogD ClogP 
pKa  
B1 
pKa 
B2 
Lung 
t½ 
h 
Residual 
dose at 
24 h (%) 
20a 9.2 7.7 7.9 0.6 2.7 9.6 4.7 4.2 0.1 
20b 9.3 7.2 8.0 0.5 2.7 9.5 6.5 23.2 4.8 
20c 9.2 7.3 8.6 2.1 4.8 9.8 8.0 12 3.3 
20d 9.1 7.0 9.0 2.5 3.5 8.4 5.4 4.5 0.2 
20e 8.8 6.6 7.9 1.1 2.6 7.3 6.0 8.7 3.5 
20f 9.2 7.1 8.9 1.7 4.2 9.7 6.8 9.9 2.8 
20g 9.1 7.2 8.7 2.0 3.8 9.0 7.0 10.9 5.2 
20h 9.1 6.6 8.9 1.4 3.8 8.0 4.0 0.0 0.0 
20i 9.2 7.9 8.5 3.2 6.1 8.8 7.5 13 3.3 
20j 8.9 6.9 8.3 1.5 4.4 8.5 5.7 5.9 0.8 
20k 8.9 7.1 8.2 1.5 4.3 8.9 6.3 7.6 3.9 
20l 9.3 7.8 8.7 2.2 5.1 9.1 7.0 17.6 7.4 
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pIC50 values for PI3Kα and γ not shown; these were consistently low (α ≤ 6.2, γ ≤ 6.7) 
All biological values are means of ≥ 3 replicates  
 
 
Figure 6.  Rat ITPK time-course profiles of selected examples. 
 
This left the question of why 20b but not 20a was retained in lung?  Previous work
16
 has 
described the benefits of dibases for lung retention, but the precise basicities required have not 
been defined.  Measured pKas for the two compounds were surprisingly different, with the 
second pKa for 20b being markedly higher than that of 20a (6.5 vs. 4.7).  To investigate this 
effect further we synthesised a set of compounds with a range of pKas for both basic centres 
(Table 4).  Inevitably these compounds (20c - l) also had varying lipophilicities; thus we also 
investigated the role of lipophilicity on both cell potency and PK.  (Figures 7 & 8) 
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 Figure 7.  Relationships between lung retention (% remaining at 24 h; half-life) and the first 
and second pKas or Lipophilicity (LogD) for dibases  
 
Examination of Figure 7 shows that, for the range of variables tested, the second (weaker) 
basic pKa is the most significant factor (6b & e).  Thus for compounds with a second pKa less 
than 5 (20a, 20h) half-life is short (< 4 h) and essentially no compound is retained in the lung 
at 24 h.  As the second pKa is increased the half-life increases but until the second pKa 
reaches >~6 only a small fraction is retained in the lung after 24 h.  With a low second pKa 
changes in lipophilicity have little effect (20a vs. 20h; 20d vs. 20j).  For compounds where 
the second pKa is greater than 6 further increases provide, in general, an increased lung half-
life, but the effect on the absolute retention is less well defined.  The first pKa (6a & d) 
appears not to play a significant role in the retention of compounds in the lung over the range 
of values in this series of compounds (lowest pKa B1 7.2).  Lipophilicity, as determined by 
LogD (also similarly for CLogP, data not shown) does not appear to affect the amount of dose 
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remaining after 24 h (6f), but does appear to contribute in a small way to the lung half-life 
(6c). 
There are two significant outliers to the analysis described above, compounds 20b & 20l.  
For both of these compounds the half-life is surprisingly long; 20l also has the highest 
percentage of sample remaining in the lung after 24 h.  20l was designed to contain an aralkyl 
chain similar to that used to improve retention in β-agonists,26 however the structurally related 
compound 20i does not exhibit any marked effect on retention.  (Both 20i and 20l surprisingly 
showed a decreased selectivity towards PI3Kβ which ruled out 20l from further progression 
despite the excellent lung retention.)   
We rationalise these results as implying that lung retention is driven by trapping of a 
dication in lung lysosomes (pH 4.5 – 527).  The monocation is membrane permeable and the 
rate of escape from the lysosome and hence half-life is driven by the fraction of monocation, 
affected by the second pKa, and lipophilicity.  The effect of lipophilicity on half-life probably 
principally derives from the greater membrane affinity of the more lipophilic compounds, thus 
the longest half-life belongs to the least lipophilic dibase 20b.  Additional structural features, 
like the long aralkyl chain of 20l, also affect the rate of membrane permeability. 
The most important driver of cell-potency appears to be the lipophilicity (Table 4, Figure 
8).  (Compounds where the second pKa is less than 6 are excluded from this analysis as they 
behave more like monobases.)  If LogD is greater than approximately 1.6 then a compound 
with good enzyme inhibition will also have good cell potency.  When a larger and more 
diverse set of dibases were examined (data not shown) the same trend was still apparent, with 
a lower cut-off of LogD ca 1.4 and an upper cut-off of ca 2.8, though structural variations did 
have an additional effect.   
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 Figure 8.  Cell drop-off for dibases. 
 
Compounds 20b & f were selected for further study based on their good lung retention, high 
potency coupled with isoform selectivity and, for 20f, excellent cell potency.  Both of these 
compounds were screened against a panel of 345 kinases, neither showed >50% activity at 
any other kinase at 1 μM.  Neither compound showed significant inhibition of the hERG ion 
channel, despite containing basic centres (< 20 % inhibition at 11 μM). 
Dosing to rats both IV and PO (table 5) showed that the compounds had negligible oral 
bioavailability and high systemic clearance with 20f exhibiting clearance greater than liver 
blood flow, implying that extrahepatic mechanisms were involved.  These results gave us 
confidence that systemic exposure of these two compounds when dosed by inhalation would 
be low.   
 
Table 5 Rat Pharmacokinetics IV and PO.  
Example IV Clearance 
mL/min/kg 
t ½ 
h 
Vss 
L/kg 
Oral bioavailability 
% 
20b 57 12 12 <1 
20f 150 11 88 <1 
All values determined from 2 animals 
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 To study the effects of the compounds in an inhaled setting we used a transgenic mouse 
model as a mechanistic model of T-cell activation.  Briefly transgenic mice (OTII strain, 
genetically sensitised to ovalbumin
28
) were challenged with ovalbumin (dosed i.t.) and then, 
after a week, dosed with compound (i.t. administration) 2h prior to a challenge with intranasal 
anti-CD3.  The animals were terminated 6 h after challenge and the inhibition of the 
formation of phospho S6 ribosomal protein (pS6RP) by compound was determined as a 
biomarker for the inhibition of PI3Kδ.29  20b showed good activity in this model with a clear 
dose response, although a high dose was required to achieve full effect (Figure 9a).  When 20f 
was dosed similarly a significant effect was observed, however instead of the 10-fold 
improvement in efficacy that we were hoping to see, based on the significantly better cell 
potency of this compound, the effect appeared to be weaker.  (Figure 9b). 
 
 
Figure 9.  Inhibition of pS6RP in lung lavage after anti-CD3 challenge to OTII mice. 9a 
compound 20b  9b compound 20f.  Target engagement of PI3Kδ activity is shown through 
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measurements of pS6RP in bronchoalveolar lung lavage cells after anti-CD3 challenge to 
OVA-challenged OTII mice.  Phosphorylation of S6RP, measured using phosphospecific 
antibodies, was significantly inhibited by both 20b (9a) and 20f (9b) in a dose-dependent 
manner, however the inhibition by 20b showed better potency.  Data is shown as results for 
individual animals at each dose with the statistical significance indicated as follows above the 
columns : p<0,001 ***; p<0,005 **; p<0,05 * 
 
 
This result left us with the question of why the more potent compound in vitro appeared to be less 
effective in-vivo?  Our rationalisation is that although 20f is retained in the lung effectively we do not 
know the available levels of drug at the target in the lung.  Compound in the lung is expected to be 
partitioned between acidic organelles, membranes and lung fluid.  Different ratios in this partitioning 
will produce differing concentrations of free drug available to act on the T-cells that drive the 
observed results.  It is also believed that, for highly permeable compounds such as this series, free 
drug in lung partitions rapidly into the systemic circulation.  Given the very high systemic clearance of 
these compounds it is unlikely that an equilibrium can be achieved and instead that free drug in the 
lung will continually be lost to the systemic circulation, resulting in very low lung free levels, once the 
initial dose has distributed.  Based on this analysis we concluded that unfortunately the combination of 
a lipophilic dibasic molecule with the very high systemic clearance exhibited by this series was 
unlikely to deliver a compound with sufficient in-vivo potency to be capable of being administered at 
the low dose necessitated by inhaled delivery and that we would require a different chemical series 
with alternative properties to deliver the effect that we desired.  
Conclusions 
We have identified a novel scaffold with excellent potency against PI3Kδ and good selectivity against 
the other isoforms, particularly PI3Kα.  Guided by crystal structure information we identified a region 
where we were able to make changes without significantly affecting biochemical potency against 
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PI3Kδ and were able to identify how to maintain selectivity against PI3Kβ.  By exploration of the 
physical properties of the compounds we were able to identify regions of property space where 
significant lung retention over 24 h and good cell potency were achievable.  From within this property 
space compounds suitable for further study were identified and we were able to show an effect in a PD 
model with i.t. dosing. 
Chemical Experimental 
All reagents obtained from commercial sources were used without further purification; 
anhydrous solvents were used without further drying.  All compounds were purified to ≥95% 
purity as judged by HPLC with uv and MS analysis.  When Cl or Br was present, expected 
isotopic distribution patterns were observed.  Details of the analytical conditions and observed 
purities are contained in the Supporting Information.  Proton (
1
H) and carbon (
13
C) NMR 
spectra were recorded at ambient temperature.  Solutions were typically prepared in 
deuterated dimethyl sulfoxide (DMSO-d6), deuteromethanol (CD3OD) or duterochloroform 
(CDCl3) with chemical shifts referenced to solvent as an internal standard.  
1
H NMR data are 
reported indicating the chemical shift (δ), the multiplicity (s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; br, broad; dd, doublet of doublets; etc.), the coupling constant (J) in Hz, 
and the integration (e.g., 1H). 
5-[(2R)-2-Chloro-1-hydroxypropylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione (3) 
A 20 L 4-necked round-bottom flask was charged with (2R)-2-chloropropanoic acid (450 g, 
4.15 mol) in dichloromethane (9 L), 2,2-dimethyl-1,3-dioxane-4,6-dione (600 g, 4.16 mol) 
and 4-dimethylaminopyridine (560 g, 4.58 mol).  A solution of DCC (946 g, 4.58 mol) in 
dichloromethane (2 L) was added dropwise with stirring at 0 ºC.  The resulting solution was 
stirred for 3 h at room temperature, recooled to 0 ºC and was then quenched by the addition of 
10 L of 6% KHSO4.  The mixture was filtered and the filtrate was extracted with 4 × 15 L of 
dichloromethane.  The combined organic layers were washed with 15 L of brine. The mixture 
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was dried over sodium sulfate and concentrated under vacuum.  The residue was 
chromatographed (silica gel; PE:EtOAc (10:1)) to give the title compound (460 g, 47%) as a 
red oil. 
1
H NMR (300 MHz, CDCl3) δ 1.72 – 1.77 (m, 9H), 6.05 (q, J = 6.8 Hz, 1H), 15.58 (s, 1H); 
m/z (ESI) 232.9 [M-H]
-
. 
7-[(1R)-1-Chloroethyl]-3-methyl-2H,3H,5H-[1,3]thiazolo[3,2-a]pyridin-5-one (4) 
A 20 L 4-necked round-bottom flask was charged with 2,4-dimethyl-4,5-dihydro-1,3-
thiazole
30
 (650 g, 5.64 mol), DCE (6.5 L), trifluoroacetic acid (643 g, 5.64 mol) and TFAA 
(1185 g, 5.64 mol).  The mixture was stirred to get a solution and was heated to 50 ºC.  A 
solution of 5-[(2R)-2-chloro-1-hydroxypropylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione (3, 
3971 g, 16.92 mol) in DCE (4 L) was added dropwise over 2 h.  The resulting solution was 
stirred overnight at 50 ºC and then allowed to cool to RT.  The pH was adjusted to 8 with aq. 
sodium bicarbonate and the resulting solution was extracted with 3 × 10 L of dichloromethane 
and the organic layers were combined.  The resulting mixture was washed with 1 x 10 L of 
brine, dried over anhydrous magnesium sulfate, concentrated and chromatographed (silica gel, 
ethyl acetate/petroleum ether (1:2-1:1)) to give the title compound (668 g, 52%) as a red oil. 
1
H NMR (400 MHz, CDCl3) δ 1.49 (d, J = 6.4 Hz, 3H), 1.71 (d, J = 6.8 Hz, 3H), 2.97 (d, J 
= 11.1 Hz, 1H), 3.67 (dd, J = 11.1, 7.5 Hz, 1H), 4.73 (q, J = 6.8 Hz, 1H), 5.2 – 5.3 (m, 1H), 
6.21 (s, 1H), 6.22 (s, 1H)); m/z (ESI) 230/232 (Cl pattern) [M+H]
+
. 
6-Bromo-7-[(1R)-1-chloroethyl]-3-methyl-2H,3H,5H-[1,3]thiazolo[3,2-a]pyridin-5-one 
(5) 
A 10 L 4-necked round-bottom flask was charged with 7-[(1R)-1-chloroethyl]-3-methyl-
2H,3H,5H-[1,3]thiazolo[3,2-a]pyridin-5-one (4, 312 g, 1.36 mol), dichloromethane (6 L), HBr 
(40% aq, 288 g, 1.42 mol) and cooled to -10 ºC.  3-Methylbutyl nitrite (318 g, 2.72 mol) was 
added dropwise with stirring and the resulting solution was stirred overnight at -5 ºC.  The 
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solution was diluted with 3 L of CH2Cl2 and was washed sequentially with 2 × 3 L of satd. 
sodium bicarbonate, 2 × 3 L of 10 % Na2S2O3 and 3 L of brine, then dried (MgSO4), filtered 
and concentrated.  The residue was chromatographed (silica gel; ethyl acetate/petroleum ether 
(1:2)) to give the title compound (295 g, 70%) as a yellow solid. 
1
H NMR (300 MHz, CDCl3) δ 1.52 (d, J = 6.4 Hz, 3H), 1.70 (d, J = 6.8 Hz, 3H), 3.00 (d, J 
= 11.2 Hz, 1H), 3.65 – 3.76 (m, 1H), 5.24 – 5.34 (m, 1H), 5.34 – 5.44 (m, 1H), 6.40 (d, J = 
2.5 Hz, 1H)); m/z (ESI) 308/310/312 (BrCl pattern) [M+H]
+
. 
6-Bromo-7-[(1R)-1-chloroethyl]-3-methyl-5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-
a]pyridin-1-ium-1-olate (6) 
A 5 L 4-necked round-bottom flask was charged with 6-bromo-7-[(1R)-1-chloroethyl]-3-
methyl-2H,3H,5H-[1,3]thiazolo[3,2-a]pyridin-5-one (5, 290 g, 940 mmol) and 
dichloromethane (3 L).  The resulting solution was cooled to 0 °C whereupon m-CPBA (178 
g, 1.0 mol) was added in several batches.  The resulting solution was stirred for 3 h and was 
then quenched by the addition of 2 L of sat. NaHCO3.  The resulting solution was extracted 
with 3 × 3 L of dichloromethane and the organic layers were combined, dried (MgSO4) and 
concentrated.  The residue was chromatographed (silica gel; ethyl acetate/petroleum ether 
(1:1-1:0)) to give the title compound (223 g, 73%) as a yellow solid. 
2 diastereomers in ca. 1:1 mixture : 
1
H NMR (300 MHz, CDCl3) δ 1.75, 1.79 (2 × d, J = 6.8 
Hz, 3H), 1.86 (d, J = 6.7 Hz, 3H), 3.14 – 3.35 (m, 2H), 5.37 – 5.53 (m, 2H), 7.16, 7.18 (2 × s, 
1H)); m/z (ESI) 324/326/328 (BrCl pattern) [M+H]
+
. 
6-Bromo-7-[(1R)-1-chloroethyl]-3-methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (7) 
A 5 L round-bottom flask was charged with 6-bromo-7-[(1R)-1-chloroethyl]-3-methyl-5-
oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyridin-1-ium-1-olate (6, 223 g, 687 mmol), toluene 
(2.3 L) and trifluoroacetic anhydride (721 g, 3.43 mol).  The resulting solution was heated to 
60 °C for 3 h, then allowed to cool and concentrated.  The residue was dissolved in 
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dichloromethane (250 mL) which was added dropwise to cooled (0 °C) sulfuric acid (98%, 
1.3 L) with stirring.  The resulting solution was stirred for 1 h at RT.  The reaction was poured 
onto water/ice and the resulting mixture was extracted with 4 × 1 L of dichloromethane.  The 
organic layers were combined, washed sequentially with 2 × 1 L of sodium bicarbonate and 1 
L of brine, dried (MgSO4), concentrated and chromatographed (silica gel; ethyl 
acetate/petroleum ether (1:5-1:2)) to give the title compound (121 g, 55%) as a yellow solid. 
1
H NMR (300 MHz, CDCl3) δ 1.76 (d, J = 6.8 Hz, 3H), 2.88 (s, 3H), 5.48 (q, J = 6.7 Hz, 
1H), 6.34 – 6.54 (m, 1H), 6.91 (s, 1H)); m/z (ESI) 308 [M+H]+. 
7-[(1S)-1-Azidoethyl]-6-bromo-3-methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (8) 
A 2 L 4-necked round-bottom flask was charged with 6-bromo-7-[(1R)-1-chloroethyl]-3-
methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (7, 118 g, 366mmol), N,N-dimethylformamide 
(1.2 L), TEA (3.88 g, 38 mmol) and NaN3 (27.5 g, 423 mmol).  The resulting solution was 
stirred for 5 h at 45 °C, allowed to cool to room temperature and poured onto water/ice.  The 
resulting mixture was extracted with 4 × 800 mL of dichloromethane and the organic layers 
were combined, washed sequentially with 10 × 1 L of 5% NaCl, dried (MgSO4) and filtered to 
give a yellow solution of the title compound that was used without further purification. 
1
H NMR (400 MHz, CDCl3) δ 1.51 (d, J = 6.7 Hz, 3H), 2.90 (d, J = 1.2 Hz, 3H), 5.12 (q, J 
= 6.7 Hz, 1H), 6.47 (d, J = 1.2 Hz, 1H), 6.77 (s, 1H), 7.28 (s, 1H)); m/z (ESI) 315 [M+H]
+
.  
7-[(1S)-1-Aminoethyl]-6-bromo-3-methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (9) 
a) From compound 8. 
A 5 L 4-necked round-bottom was charged with a solution of 7-[(1S)-1-azidoethyl]-6-
bromo-3-methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one in dichloromethane (3000 mL, 
previous step) and triphenylphosphine (87.5 g, 334 mmol).  The resulting solution was 
heated to 50 ºC for 3 h, allowed to cool and concentrated.  The residue was dissolved in 
THF (800 mL) and water (400 mL) and the resulting solution was heated overnight at 50 °C 
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and then allowed to cool.  The mixture was concentrated and the residue was 
chromatographed (silica gel; methanol/dichloromethane (1:100 to 1:20)) to give the title 
compound (52 g, 60%) as a yellow solid. 
1
H-NMR (300MHz, CD3OD) δ 1.31 (3H, d J = 6.6 Hz), 2.78 (3H, s), 4.40 (1H, q J = 6.6 
Hz), 6.84 (1H, s), δ 7.05 (1H, s)); m/z (ESI) 287 [M+H]+. 
b) from compound 10 
(S)-Benzyl (1-(6-bromo-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)carbamate 
(10, 10 g, 23.7 mmol) was dissolved in CH2Cl2 (200 mL) and cooled to 0°C.  Boron 
tribromide (59.5 g, 237 mmol) was added dropwise over a period of 15 minutes.  The 
resulting mixture was stirred at RT for 3 hours.  The reaction mixture was poured onto ice 
(150 mL) and extracted with CH2Cl2 (3 × 100 mL).  The aqueous layer was adjusted to pH = 
9 with saturated sodium carbonate and was extracted with CH2Cl2 (3 × 25 mL).  The solvent 
was removed under reduced pressure and the residue was dried under vacuum to give the title 
compound (5.50 g, 81 %) as a yellow solid. 
1
H NMR (500 MHz, DMSO) δ 1.19 (d, J = 6.6 Hz, 3H), 2.00 (s, 2H), 2.71 (s, 3H), 4.23 (q, 
J = 6.6 Hz, 1H), 7.02 (s, 1H);
13C NMR (126 MHz, DMSO) δ 17.99, 22.99, 50.64, 97.30, 
97.86, 104.08, 108.93, 137.44, 148.75, 157.18); m/z (ESI) 287 [M+H]
+
.  
Benzyl [(1S)-1-(6-bromo-3-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyridin-7-
yl)ethyl]carbamate (10) 
A 3 L 4-necked round-bottom flask was charged with 7-[(1S)-1-aminoethyl]-6-bromo-3-
methyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (9, 52 g, 181 mmol) in THF/H2O (10:1, 1.1 L) 
and potassium carbonate (62.6 g, 453 mmol) and cooled to 0 °C.  Cbz-Cl (46.4 g, 272 mmol) 
was added dropwise and the resulting mixture was stirred overnight at room temperature.  
Water (3 L) was added, the solids were collected by filtration, washed with water (5 × 200 
mL) and then with THF/Hexane (1:2) (3 × 200 mL).  The crude product was purified by 
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preparative-SFC (CHIRALPAK IC SFC, 5 × 25 cm, 5 μm; mobile phase A CO2 (50%), B 
methanol : CH2Cl2 = 2:1(0.2% diethylamine)(50%); detection, UV 220 nm) to give the title 
compound (23.5 g, 31%) as a light yellow solid. 
1
H NMR (300 MHz, CD3OD) δ 1.17 (d, J = 7.0 Hz, 3H), 2.80 (s, 3H), 4.58 (s, 1H), 5.04 (s, 
2H), 6.83 (s, 1H), 6.94 (s, 1H), 7.11 – 7.51 (m, 5H); m/z (ESI) 421 [M+H]+; αD -60.5 ° (c = 
5.30 g/L CH2Cl2, 21-7 ºC); SFC Chiralpak IC-3 5.0 μm; 100 × 4.6 mm; Mobile phase A: CO2 
B:methanol/0.1% diethylamine Tr 1.47 min; e.r 97.7 : 2.3 (minor isomer Tr 1.14 min) 
Benzyl (1-(3-methyl-5-oxo-6-phenyl-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)carbamate 
(11) 
Cs2CO3 (1083 mg, 3.32 mmol), phenylboronic acid (152 mg, 1.25 mmol), PdCl2(dppf)-
CH2Cl2 adduct (68 mg, 0.08 mmol) and (±) benzyl (1-(6-bromo-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)carbamate (10, 350 mg, 0.83 mmol) were slurried in DME 
(10 mL) and water (2 mL) and heated to 100 ºC for 30 minutes in a microwave.  The solvent 
was evaporated and the crude product was purified by flash chromatography (silica; 80 to 
20% petroleum ether in EtOAc) to give the title compound (236 mg, 68 %) as a yellow solid. 
1
H NMR (300 MHz, CD3OD) δ 1.17 (d, J = 7.0 Hz, 3H), 2.80 (s, 3H), 4.58 (s, 1H), 5.04 (s, 
2H), 6.83 (s, 1H), 6.94 (s, 1H), 7.11 – 7.51 (m, 11H); m/z (ESI) 419 [M+H]+. 
7-(1-Aminoethyl)-3-methyl-6-phenyl-5H-thiazolo[3,2-a]pyridin-5-one (12) 
To a solution of benzyl N-(1-[3-methyl-5-oxo-6-phenyl-5H-[1,3]thiazolo[3,2-a]pyridin-7-
yl]ethyl) carbamate (11, 240 mg, 0.57 mmol) in dichloromethane (6 mL) at 0 ºC, was added 
boron tribromide (863 mg, 3.44 mmol, 6 eq) dropwise.  The resulting solution was stirred for 
20 h at room temperature and then cooled to 0 ºC.  The reaction was quenched by the addition 
of water/ice, the pH was adjusted to 8 with sodium carbonate (aq.), and the mixture was 
extracted with chloroform.  The organic layers were combined, dried over anhydrous sodium 
sulfate, and concentrated to give the title compound (120 mg, 74%) as a light yellow solid. 
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1
H NMR (400 MHz, DMSO) δ 1.05 (d, J = 6.5 Hz, 3H), 1.93 (s, 2H), 2.68 (s, 3H), 3.68 (q, 
J = 6.6, 1H), 6.91 (s, 1H), 7.09 (s, 1H), 7.20 (d, J = 6.0 Hz, 2H), 7.30 (t, J = 7.3 Hz, 1H), 7.39 
(t, J = 7.4, Hz, 2H), 7.50 – 7.67 (m, 1H); m/z (ESI) 285 [M+H]+. 
(S)-4-Amino-6-[(1-[3-methyl-5-oxo-6-phenyl-5H-[1,3]thiazolo[3,2-a]pyridin-7-
yl]ethyl)amino]pyrimidine-5-carbonitrile (13) 
7-(1-Aminoethyl)-3-methyl-6-phenyl-5H-[1,3]thiazolo[3,2-a]pyridin-5-one (12, 268 mg, 
0.94 mmol) and 4-amino-6-chloropyrimidine-5-carbonitrile
31
 (145 mg, 0.94 mmol) were 
dissolved in n-butanol (12 mL).  DIEA (1.21 g, 9.36 mmol) was added and the resulting 
solution was heated to 120 °C for 2 h, allowed to cool and then concentrated.  
Recrystallisation (ethyl acetate) gave the title compound (130 mg, 34%) as a light yellow 
solid.  The enantiomers were separated by chiral HPLC (Reprosil NR column 250 × 20 mm 
eluting with heptane : EtOAc : TEA (40:60:0.1)) collecting the first eluting peak which was 
then further purified by preparative SFC (Phenomenex Luna Hilic 250 × 30 mm eluting with 
20 mM ammonia in methanol) to give the title compound (16 mg). 
1
H NMR (500 MHz, DMSO-d6) δ 1.23 (d, J = 7.1 Hz, 3H), 2.67 (d, J = 1.2 Hz, 3H), 4.91 
(quint, J = 7.0 Hz, 1H), 6.91 – 6.94 (m, 1H), 6.97 (s, 1H), 7.05 – 7.60 (m, 5H), 7.22 (brs, 2H), 
7.48 (d, J = 7.0 Hz, 1H), 7.95 (s, 1H);  
13
C NMR (126 MHz, DMSO-d6) δ 18.09, 20.54, 
47.72, 67.92, 96.08, 107.52, 115.41, 120.28, 126.76, 127.78 (2C), 130.71 (2C), 136.00, 
137.51, 148.16, 152.48, 159.43, 160.88, 161.57, 164.33;  m/z (ESI) 403 [M+H]
+
; HRMS 
calculated for C21H18N6OS [(M + H)+], 403.1341; found, 403.1345. 
(S)-4-Amino-6-((1-(6-bromo-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (14) 
(S)-7-(1-Aminoethyl)-6-bromo-3-methyl-5H-thiazolo[3,2-a]pyridin-5-one (9, 1.5 g, 5.2 
mmol) and 4-amino-6-chloropyrimidine-5-carbonitrile (0.888 g, 5.75 mmol) were dissolved 
in n-butanol (20 mL).  DIEA (9.12 mL, 52.23 mmol) was added and the resulting solution 
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was stirred at 120 ºC for 12 hours. The solvent was evaporated, the reaction mixture was 
diluted with EtOAc, and the residual solid was collected to give the title compound (1.50 g, 
71 %) as a yellow solid.   
1
H NMR (500 MHz, DMSO-d6) δ 1.44 (d, J = 7.1 Hz, 3H), 2.72 (d, J = 1.0 Hz, 3H), 5.38 
(quint, J = 7.1 Hz, 1H), 6.92 (s, 1H), 7.02 (d, J = 1.2 Hz, 1H), 7.28 (brs, 2H), 7.72 (d, J = 7.1 
Hz, 1H), 7.93 (s, 1H);
13
C NMR (126 MHz, DMSO-d6) δ 18.0, 19.4, 50.6, 68.3, 96.7, 104.2, 
109.1, 115.3, 137.6, 149.0, 153.9, 157.3, 159.6, 161.7, 164.3; m/z (ESI) 405 [M+H]
+
.[M+H]+ 
= 405. 
(S)-4-Amino-6-((1-(6-(3-(aminomethyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-
a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15a)  
(S)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (14, 80 mg, 0.20 mmol) was added to a solution of  
(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)boronic acid (198 mg, 0.79 mmol), cesium 
carbonate (257 mg, 0.79 mmol) and PdCl2(dppf)-CH2Cl2 adduct (16 mg, 0.02 mmol) in DME 
(2.5 mL) and water (1ml) at 25 °C over a period of 10 minutes under nitrogen.  The reaction 
was heated to 100 ºC for 45 minutes in a microwave reactor and then cooled to RT.  The 
solvent was evaporated and the residue was purified by flash silica chromatography, elution 
gradient 60 to 40% petroleum ether in EtOAc to give the (S)-tert-butyl 3-(7-(1-((6-amino-5-
cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-6-
yl)benzylcarbamate (90 mg, 86 %) as a yellow solid.  
TFA (2 mL, 25.96 mmol) was added to (S)-tert-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-
4-yl)amino)ethyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl)benzylcarbamate (80 mg, 
0.15 mmol) in CH2Cl2 (4 mL) under nitrogen.  The resulting solution was stirred at room 
temperature for 16 hours. The solvent was evaporated and the residue was purified by 
preparative HPLC with the following conditions: Column: X Bridge C18, 19 × 150 mm, 5 um; 
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Mobile Phase A:Water/0.05% TFA, Mobile Phase B: MeCN; Flow rate: 20 mL/min; 
Gradient: 30%B to 70%B in 10 min; 254 nm to give the title compound (60 mg, 73 %) as a 
yellow solid.  
1
H NMR (300 MHz, CD3OD) δ 1.30-1.45 (m, 3H), 2.82 (s, 3H), 4.17 (s, 2H), 5.13-5.23 (m, 
1H), 6.86 – 6.93 (m, 1H), 7.05 (s, 1H), 7.36 (s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 7.5 
Hz, 1H), 7.66 (s, 1H), 8.00-8.25 (m, 1H); m/z (ESI) 432 [M+H]
+
. 
General procedure for synthesis of compounds 15b-g, 20a-g: 
Aldehyde 16 (65 mg, 0.15 mmol) was dissolved in a mixture of methanol and 
dichloromethane (1:1, 10 mL) and the solution was cooled in ice.  Sodium cyanoborohydride 
(14 mg, 1.5 eq) and acetic acid (43 μL, 5 eq) were added followed by the amine (neat or as a 
solution; 1 eq) over a period of 15 min.  The mixture was allowed to stir overnight at ambient 
temperature then water (0.5 mL) was added and the mixture was concentrated.  The residue 
was purified by preparative HPLC (Waters XBridge Prep C18 OBD or Phenyl OBD column, 
5µ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water 
(containing 10% NH4HCO3) and MeCN as eluents to give the pure products. 
(S)-4-Amino-6-((1-(3-methyl-6-(3-((methylamino)methyl)phenyl)-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15b)  
1
H NMR (300 MHz, CD3OD) δ 1.27 – 1.43 (m, 3H), 2.76 (s, 3H), 2.81 (d, J = 1.1 Hz, 3H), 
4.16 – 4.29 (m, 2H), 4.98 – 5.14 (m, 1H), 6.87 (d, J = 1.2 Hz, 1H), 7.05 (s, 1H), 7.33 – 7.78 
(m, 4H), 7.96 (s, 1H); m/z (ESI) 446 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-((dimethylamino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15c)  
1
H NMR (300 MHz, DMSO) δ 1.24 (d, J = 7.0 Hz, 3H), 2.35 (s, 6H), 2.68 (d, J = 1.2 Hz, 
3H), 3.71 (s, 2H), 4.89 (s, 1H), 6.94 (d, J = 1.3 Hz, 1H), 7.00 (s, 1H), 7.1 – 7.34 (m, 4H), 7.36 
– 7.44 (m, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.95 (s, 1H), 8.14 (s, 1H); m/z (ESI) 460 [M+H]+. 
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(S)-4-Amino-6-((1-(6-(3-(((2-methoxyethyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15d)  
1
H NMR (300 MHz, CD3OD) δ 1.32 (d, J = 6.9 Hz, 3H), 2.79 (d, J = 1.1 Hz, 5H), 3.48 (s, 
2H), 3.84 (s, 2H), 5.10 (d, J = 7.1 Hz, 1H), 6.82 (d, J = 1.2 Hz, 1H), 7.01 (s, 1H), 7.22 (m, 
1H), 7.34 (d, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.55 (m, 1H), 7.96-8.01 (m, 1H) (3H 
obscured); m/z (ESI) 490 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-((isobutyl(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-
thiazolo(3,2-a)pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15e)  
1H NMR (300 MHz, DMSO) δ 0.82 (d, J = 6.4 Hz, 6H), 1.22 (d, J = 7.0 Hz, 3H), 1.76 (s, 
1H), 2.07 (s, 5H), 2.67 (s, 3H), 3.43 (s, 2H), 4.84 – 5.01 (m, 1H), 6.92 (s, 1H), 6.97 (s, 1H), 
7.23 (s, 3H), 7.33 (s, 2H), 7.48 (d, J = 6.9 Hz, 1H), 7.93 (s, 1H); m/z (ESI) 502 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-(azetidin-1-ylmethyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-
a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15f)  
1
H NMR (300 MHz, CD3OD) δ 1.33 (d, J = 7.1 Hz, 3H), 2.22 (s, 2H), 2.68 – 2.9 (m, 3H), 
3.54 (s, 4H), 3.85 (s, 2H), 5.06 (s, 1H), 6.83 (d, J = 1.1 Hz, 1H), 7.01 (s, 1H), 7.25 (s, 1H), 
7.33 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.56 (s, 1H), 7.96 – 8.02 (m, 1H); m/z (ESI) 
472 [M+H]
+
. 
(S)-4-Amino-6-((1-(3-methyl-5-oxo-6-(3-(((4-phenethoxybutyl)amino)methyl)phenyl)-
5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (15g)  
1
H NMR (400MHz; CD3OD) δ 1.28-1.42 (3H, m), 1.67-1.79 (4H, d), 2.67-2.86 (5H,m), 
2.98-3.09 (2H, m), 3.50-3.51 (2H, m), 3.67.(2H, s), 4.17-4.19 (2H,d), 3.57 (2H,s), 5.00-5.20 
(1H, m), 6.89 (1H, s), 7.06 (1H, s), 7.15-7.28 (5H, m),7.44-7.46 (2H, d),7.50-7.75 (2H, m), 
8.00 (1H, s); m/z (ESI) 608 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-formylphenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (16) 
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(3-Formylphenyl)boronic acid (370 mg, 2.47 mmol) was added to (S)-4-amino-6-((1-(6-
bromo-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile 
(14, 500 mg, 1.23 mmol), cesium carbonate (804 mg, 2.47 mmol) and PdCl2(dppf)-CH2Cl2 
adduct (101 mg, 0.12 mmol) in DME (10 mL) and water (3ml) at 25°C over a period of 15 
minutes under nitrogen.  The reaction was heated to 100 ºC for 30 minutes in a microwave 
reactor and cooled to RT.  The reaction mixture was quenched with water (10 mL), extracted 
with EtOAc (3 x 10 mL), the organic layer was dried over Na2SO4, filtered and evaporated.  
The crude product was purified by flash silica chromatography, elution gradient 30 to 50% 
EtOAc in petroleum ether to give the title compound (400 mg, 75 %) as a white solid.  
1
H NMR (500 MHz, DMSO-d6) δ 1.26 (d, J = 7.1 Hz, 3H), 2.68 (d, J = 1.1 Hz, 3H), 4.86 
(quint, J = 7.0 Hz, 1H), 6.96 (d, J = 1.3 Hz, 1H), 7.05 (s, 1H), 7.23 (brs, 2H), 7.56 (d, J = 7.1 
Hz, 1H), 7.61 – 7.67 (m, 1H), 7.84 – 7.88 (m, 1H), 7.94 (s, 1H), 7.4 – 8.2 (vbrm, 2H), 10.05 
(s, 1H). Note: aromatic protons 2 and 6 from the 3-formylphenyl ring are observed as very 
broad signals in baseline between 7.4-8.2 ppm;
 13
C NMR (126 MHz, DMSO) δ 18.0, 20.5, 
47.7, 67.9, 96.4, 107.8, 115.4, 118.9, 128.0, 128.7, 132.2, 136.0, 137.0, 137.1, 137.6, 152.6, 
159.4, 160.7, 161.5, 164.3, 193.2; m/z (ESI) 431 [M+H]
+
.  
(S)-4-Amino-6-((1-(6-(3-(2-(dimethylamino)ethyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile formic acid salt (17)  
Step 1 
3rd Generation PCy3 precatalyst
32
 (48 mg, 0.07 mmol), (S)-4-amino-6-((1-(6-bromo-3-
methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (300 mg, 
0.74 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate 
(514 mg, 1.48 mmol potassium phosphate (471 mg, 2.22 mmol) and Cy3P.HBF4 (54.5 mg, 
0.15 mmol) were mixed in dioxane (12 mL)/water (3 mL) and sealed into a microwave tube.  
The reaction was heated to 130 °C for 1 hour in the microwave reactor and cooled to RT.  The 
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reaction mixture was diluted with CH2Cl2 (150 mL), and washed with water (100 mL×1), and 
saturated brine (100 mL×1). The organic layer was dried over Na2SO4, filtered and 
evaporated.  The residue was purified by flash silica chromatography, elution gradient 20 to 
50% EtOAc in petroleum ether to give (S)-tert-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-
yl)amino)ethyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl)phenethylcarbamate (180 mg, 
45 %) as a yellow solid.  
Step 2 
TFA (2.5 mL, 33 mmol) was added to (S)-tert-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-
yl)amino)ethyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-6-yl)phenethylcarbamate (180 mg, 
0.33 mmol) in CH2Cl2 (5 mL) at 25 °C under nitrogen.  The resulting mixture was stirred at 
25 °C for 4 h.  The solvent was removed under reduced pressure and the crude product was 
purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C18 OBD column, 5µ 
silica, 19 mm diameter, 100 mm length), using water (containing 1 % TFA) and MeCN as 
eluents to give (S)-4-amino-6-((1-(6-(3-(2-aminoethyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (130 mg, 70 %) as a pale 
yellow solid.  
1
H NMR (300 MHz, CD3OD) δ 1.32 – 1.45 (m, 3H), 2.81 (d, J = 0.9 Hz, 3H), 2.9 – 3.1 (m, 
2H), 3.15 – 3.3 (m, 2H), 5.03 – 5.21 (m, 1H), 6.88 (s, 1H), 6.99 – 7.58 (m, 5H), 7.96 – 8.13 
(m, 1H). 
Step 3 
Sodium cyanoborohydride (11 mg, 0.18 mmol) was added to (S)-4-amino-6-((1-(6-(3-(2-
aminoethyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-
5-carbonitrile (40 mg, 0.09 mmol), formaldehyde (20 mg, 0.27 mmol) and AcOH (0.026 mL, 
0.45 mmol) in MeOH (5 mL) at 25 ºC.  The resulting mixture was stirred at 25 °C for 3 h.  
The crude product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep 
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C18 OBD column, 5µ silica, 19 mm diameter, 100 mm length), using water (containing 1% 
Formic acid) and MeCN as eluents to give the title compound (9 mg, 20 %) as a pale yellow 
solid.  
1
H NMR (300 MHz, CD3OD) δ 1.26 – 1.41 (m, 3H), 2.74 – 2.89 (m, 9H), 2.96 – 3.11 (m, 
2H), 3.19 – 3.36 (m, 2H), 4.98 – 5.16 (m, 1H), 6.84 – 6.86 (m, 1H), 7.00 – 7.07 (m, 1H), 7.14 
– 7.24 (m, 1H), 7.25 – 7.34 (m, 1H), 7.38 – 7.57 (m, 2H), 7.95 (s, 1H), 8.54 (s, 1H); m/z (ESI) 
490 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-(2-(dimethylamino)ethoxy)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile formic acid salt (18)  
Step 1 
3
rd
 Generation PCy3 precatalyst
32
 (48.1 mg, 0.07 mmol), PCy3.HBF4 (54.5 mg, 0.15 mmol), 
(S)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (14, 100 mg, 0.25 mmol), 3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenol (163 mg, 0.74 mmol) and K3PO4 (157 mg, 0.74 mmol) were 
dissolved in dioxane (12 mL)/H2O (2mL) and sealed into a microwave tube.  The reaction 
was heated to 130 ºC for 1 h.  The reaction mixture was diluted with CH2Cl2 (200 mL), and 
washed sequentially with saturated NaHCO3 (100 mL), water (100 mL), and saturated brine 
(100 mL).  The organic layer was dried over Na2SO4, filtered and evaporated.  The crude 
product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C18 OBD 
column, 5µ, 19 × 100 mm; gradient MeCN in 1% aq TFA) to give (S)-4-Amino-6-((1-(6-(3-
hydroxyphenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-
carbonitrile (80 mg, 61 %) as a yellow solid.  
1
H NMR (400 MHz,CD3OD) δ 1.40 (d, J = 6.8 Hz, 3H), 2.79 (s, 3H), 5.22 (s, 1H), 6.76 (s, 
2H), 6.84 (s, 1H), 6.99 (s, 2H), 7.24 (t, J = 7.8, 7.8 Hz, 1H), 8.07 (s, 1H). 
Step 2 
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DEAD (75 mg, 0.43 mmol) was added to (S)-4-amino-6-((1-(6-(3-hydroxyphenyl)-3-
methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (60 mg, 
0.14 mmol), 2-(dimethylamino)ethanol (19 mg, 0.22 mmol) and triphenylphosphine (113 mg, 
0.43 mmol) in THF (10 mL) at 0 ºC over a period of 2 minutes under nitrogen.  The resulting 
solution was stirred at 40 °C for 12 hours.  The solvent was removed under reduced pressure 
and the crude product was purified by preparative HPLC (XBridge Prep C18 OBD column, 5µ 
silica, 19 mm diameter, 150 mm length), using water (containing 0.05 % Formic acid) and 
MeCN as eluents to give the title compound (10 mg, 13 %) as a white solid.  
1
H NMR (300 MHz, CD3OD) δ 1.34 (d, J = 7.1 Hz, 3H), 2.58 (s, 6H), 2.80 (s, 3H), 3.03 – 
3.14 (m, 2H), 4.15 – 4.29 (m, 2H), 5.07 – 5.19 (m, 1H), 6.8 – 6.92 (m, 2H), 6.93 – 6.99 (m, 
1H), 7.00 (s, 1H), 7.15 – 7.25 (m, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.95 (s, 1H), 8.52 (s, 1H); m/z 
(ESI) 474 [M+H]
+
. 
(S)-4-Amino-6-((1-(3-methyl-5-oxo-6-(3-((1-(3,3,3-trifluoropropyl)piperidin-4-
yl)methyl)phenyl)-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile 
(19) 
Step 1 
PdCl2(dppf)-CH2Cl2 adduct (100 mg, 0.12 mmol), (S)-4-amino-6-((1-(6-bromo-3-methyl-5-
oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (14, 250 mg, 0.62 
mmol), tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine-1-
carboxylate
33
 (990 mg, 2.47 mmol) and cesium carbonate (804 mg, 2.47 mmol) were 
dissolved in dioxane (12 mL)/water (4 mL) and sealed into a microwave tube.  The reaction 
was heated to 130 ºC for 2 hours in a microwave reactor and cooled to RT.  The reaction 
mixture was diluted with EtOAc (100 mL), and washed sequentially with water (100 mL × 1) 
and saturated brine (100 mL × 1). The organic layer was dried over Na2SO4, filtered and 
evaporated.  The residue was purified by preparative TLC (EtOAc: petroleum ether = 1: 1), to 
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give tert-butyl 4-[3-(7-{(1S)-1-[(6-amino-5-cyanopyrimidin-4-yl)amino]ethyl}-3-methyl-5-
oxo-5H-[1,3]thiazolo[3,2-a]pyridin-6-yl)benzyl]piperidine-1-carboxylate (260 mg, 70 %) as a 
yellow solid.  
Step 2  
TFA (1.5 mL, 19 mmol) was added to (S)-tert-butyl 4-(3-(7-(1-((6-amino-5-
cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-6-
yl)benzyl)piperidine-1-carboxylate (260 mg, 0.43 mmol) in CH2Cl2 (20 mL) at 0 °C over a 
period of 15 minutes under nitrogen.  The resulting solution was stirred for 12 hours.  The 
reaction mixture was quenched with saturated NaHCO3 (20 mL), extracted with CH2Cl2 (3 × 
10 mL), the organic layer was dried over Na2SO4, filtered and evaporated to give (S)-4-
amino-6-((1-(3-methyl-5-oxo-6-(3-(piperidin-4-ylmethyl)phenyl)-5H-thiazolo[3,2-a]pyridin-
7-yl)ethyl)amino)pyrimidine-5-carbonitrile (230 mg, 106 %) as a yellow solid that was used 
without further purification. 
Step 3  
NaCNBH3 (15 mg, 0.24 mmol) was added to (S)-4-amino-6-((1-(3-methyl-5-oxo-6-(3-
(piperidin-4-ylmethyl)phenyl)-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-
carbonitrile (60 mg, 0.12 mmol), 3,3,3-trifluoropropanal (53.8 mg, 0.48 mmol) and AcOH 
(0.034 mL, 0.60 mmol) in a mixture of CH2Cl2 (5 mL) and MeOH (5 mL) were added at 
25 °C over a period of 15 minutes.  The resulting mixture was stirred at 45 °C for 12 hours.  
The solvent was evaporated and the residue was purified by preparative HPLC (XBridge Prep 
C18 OBD column, 5µ silica, 19 mm diameter, 150 mm length), using decreasingly polar 
mixtures of water (containing 0.5% TFA) and MeCN as eluents to give the title compound 
(20 mg, 16 %) as a yellow solid.  
1
H NMR (300 MHz, CD3OD) δ 1.27 – 1.41 (m, 10H), 1.42 – 1.61 (m, 2H), 1.88 – 2.08 (m, 
4H), 2.66 (d, J = 6.6 Hz, 2H), 2.80 (d, J = 1.0 Hz, 3H), 2.87 – 3.06 (m, 3H), 3.36 – 3.52 (m, 
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3H), 5.06 – 5.21 (m, 1H), 6.86 (d, J = 1.2 Hz, 1H), 7.02 (s, 1H), 7.07 – 7.22 (m, 2H), 7.33 – 
7.44 (m, 2H), 8.04 (s, 1H); m/z (ESI) 596 [M+H]
+
. 
Compounds 20a – 20g synthesised following procedure described earlier for 15b-g 
((S)-4-Amino-6-((1-(3-methyl-6-(3-(((2-morpholinoethyl)amino)methyl)phenyl)-5-oxo-
5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20a)  
1
H NMR (300 MHz, DMSO-d6) δ 1.22 (d, J = 7.0 Hz, 3H), 1.94 – 2.4 (m, 7H), 2.53 – 2.62 
(m, 2H), 2.68 (s, 3H), 3.4 – 3.56 (m, 4H), 3.72 (s, 2H), 4.85 – 4.99 (m, 1H), 6.92 (d, J = 1.2 
Hz, 1H), 6.97 (s, 1H), 7.02 – 7.61 (m, 7H), 7.97 (s, 1H); m/z (ESI) 545 [M+H]+. 
(S)-4-Amino-6-((1-(6-(3-((4-(dimethylamino)piperidin-1-yl)methyl)phenyl)-3-methyl-5-
oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20b)  
1
H NMR (500 MHz, DMSO-d6) δ 1.22 (d, J = 7.0 Hz, 3H), 1.27 – 1.40 (m, 2H), 1.57 – 
1.75 (m, 2H), 1.83 – 1.98 (m, 2H), 2.00 – 2.12 (m, 1H), 2.15 (s, 6H), 2.68 (s, 3H), 2.76 – 2.91 
(m, 2H), 3.44 (s, 2H), 4.84 – 4.96 (m, 1H), 6.91 – 6.94 (m, 1H), 6.98 (s, 1H), 7.00 – 7.47 (m, 
6H), 7.48 (d, J = 7.1 Hz, 1H), 7.94 (s, 1H); 
13
C NMR (126 MHz, DMSO-d6) δ 18.14, 20.51, 
27.90 (2C), 41.33 (2C), 47.72, 52.36, 52.46, 61.68, 62.18, 67.90, 96.23, 107.55, 115.44, 
120.39, 127.19, 127.57, 129.19, 130.99, 135.74, 137.53, 138.11, 148.11, 152.42, 159.40, 
160.87, 161.56, 164.36; m/z (ESI) 543 [M+H]
+
; HRMS calculated for C29H35N8OS [(M + 
H)+], 543.2649; found, 543.2641 
(S)-4-Amino-6-((1-(6-(3-((4-((isobutyl(methyl)amino)methyl)piperidin-1-
yl)methyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (20c)  
1
H NMR (400 MHz, CD3OD) δ 0.88 (d, J = 6.0 Hz, 6H), 1.18-1.35 (m, 5H), 1.50-1.82 (m, 
4H), 2.0-2.35 (m, 9H), 2.71 – 2.87 (m, 3H), 3.06 (s, 2H), 3.71 (s, 2H), 5.05 (s, 1H), 6.83 (s, 
1H), 7.01 (s, 1H), 7.26 (s, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.44 (t, J = 7.6, 7.6 Hz, 1H), 7.52-
7.61 (m, 1H), 7.92-8.02 (m, 1H) 3H obscured; m/z (ESI) 599 [M+H]
+
. 
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(S)-4-Amino-6-((1-(3-methyl-6-(3-((4-(methyl(3,3,3-trifluoropropyl)amino)piperidin-1-
yl)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-
carbonitrile (20d)  
1
H NMR (400 MHz, CD3OD) δ 1.34-1.46 (m, 3H), 2.14 (s, 2H), 2.28-2.41 (m, 2H), 2.79-
2.94 (m, 8H), 3.18 (t, J = 12.2 Hz, 2H), 3.47-3.53 (m, 2H), 3.63-3.86 (m, 3H), 4.41 (d, J = 
15.0 Hz, 2H), 5.00-5.21 (1H, m), 6.90 (s, 1H), 7.05 (s, 1H), 7.39-7.76 (m, 4H), 8.10 (s, 1H); 
3H obscured; 
19
F NMR (376 MHz; CD3OD) δ -66.6; m/z (ESI) 625 [M+H]
+
. 
(S)-4-Amino-6-((1-(3-methyl-6-(3-((4-(2-morpholinoethyl)piperazin-1-
yl)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-
carbonitrile (20e)  
1
H NMR (300 MHz, CD3OD) δ 1.24 – 1.57 (m, 3H), 2.35 – 2.63 (m, 2H), 2.71 – 2.95 (m, 
5H), 3.03 – 3.31 (m, 7H), 3.44 – 3.72 (m, 5H), 3.83 – 4.08 (m, 4H), 4.3 – 4.52 (m, 2H), 5.16 
(s, 1H), 6.91 (s, 1H), 7.07 (s, 1H), 7.36 – 7.55 (m, 2H), 7.54 – 7.67 (m, 1H), 7.78 (s, 1H), 8.06 
(s, 1H); m/z (ESI) 614 [M+H]
+
. 
(S)-4-amino-6-((1-(6-(3-((4-(isobutyl(methyl)amino)piperidin-1-yl)methyl)phenyl)-3-
methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20f)  
1
H NMR (500 MHz, DMSO-d6) δ 0.80 (d, J = 6.6 Hz, 6H), 1.22 (d, J = 7.0 Hz, 3H), 1.29 – 
1.44 (m, 2H), 1.46 – 1.66 (m, 3H), 1.81 – 1.95 (m, 2H), 2.05 (d, J = 6.9 Hz, 2H), 2.10 (s, 3H), 
2.16 – 2.28 (m, 1H), 2.68 (s, 3H), 2.76 – 2.91 (m, 2H), 3.44 (brs, 2H), 4.84 – 5.01 (brm, 1H), 
6.91 – 6.94 (m, 1H), 6.98 (s, 1H), 7.01 – 7.45 (m, 6H), 7.47 (d, J = 7.0 Hz, 1H), 7.94 (s, 1H); 
13
C NMR (126 MHz, DMSO-d6) δ 18.14, 20.49, 20.66 (2C), 26.03, 27.41 (2C), 38.04, 47.71, 
52.93 (2C), 61.08, 61.40, 62.23, 67.90, 96.22, 107.55, 115.44, 120.38, 127.14, 127.54, 
129.20, 130.92, 135.72, 137.53, 138.24, 148.11, 152.43, 159.39, 160.88, 161.56, 164.35; m/z 
(ESI) 585 [M+H]
+
; HRMS calculated for C32H41N8OS [(M + H)+], 585.3124; found, 
585.3109 
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(S)-4-Amino-6-((1-(3-methyl-6-(3-((4-((methyl(pyridin-2-
ylmethyl)amino)methyl)piperidin-1-yl)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-
7-yl)ethyl)amino)pyrimidine-5-carbonitrile formic acid salt (20g)  
1
H NMR (400 MHz, CD3OD) δ 1.18 – 1.48 (m, 5H), 1.82 – 2.17 (m, 3H), 2.33 (s, 3H), 2.41 
(d, J = 5.5 Hz, 2H), 2.81 (s, 3H), 2.9 – 3.05 (m, 2H), 3.39 – 3.61 (m, 2H), 3.74 (s, 2H), 4.17 – 
4.37 (m, 2H), 4.93 – 5.16 (m, 1H), 6.87 (s, 1H), 7.05 (s, 1H), 7.3 – 7.35 (m, 1H), 7.35 – 7.79 
(m, 5H), 7.79 – 7.86 (m, 1H), 7.96 (s, 1H), 8.42 (brs, 1H), 8.48 (d, J = 4.4 Hz, 1H); m/z (ESI) 
634 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-((ethyl(2-morpholinoethyl)amino)methyl)phenyl)-3-methyl-5-
oxo-5H-thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20h)  
Sodium cyanoborohydride (23 mg, 0.37 mmol) was added to (S)-4-amino-6-((1-(3-methyl-
6-(3-(((2-morpholinoethyl)amino)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (20a, 100 mg, 0.18 mmol), acetaldehyde (12 mg, 
0.28 mmol) and acetic acid (0.053 mL, 0.92 mmol) in CH2Cl2 (5 mL) and MeOH (10 mL) at 
25 °C.  The resulting mixture was stirred at 25 °C for 12 hours.  The solvent was removed 
under reduced pressure.  The crude product was purified by preparative HPLC (Phenomenex 
Gemini-NX axia Prep C18 OBD column, 5µ silica, 19 mm diameter, 100 mm length), using 
decreasingly polar mixtures of water (containing 1% NH4HCO3) and MeCN as eluents to give 
the title compound (55 mg, 52 %) as a white solid. 
1
H NMR (300 MHz, CD3OD): δ 1.05 - 1.13 (m, 3H), 1.23 - 1.33 (m, 3H), 2.38 - 2.80 (m, 
10H), 2.85 (s, 3H), 3.54 - 3.84 (m, 6H), 5.03 - 5.12 (m, 1H), 6.81 (d, J = 1.2 Hz, 1H), 6.99 (s, 
1H), 7.14 - 7.67 (m, 4H), 7.94 - 8.02 (m, 1H); m/z (ESI) 573 [M+H]
+
. 
(S)-4-Amino-6-((1-(6-(3-(((3-((4-
chlorobenzyl)(methyl)amino)propyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20i)  
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Prepared from aldehyde 16 and N
1
-(4-chlorobenzyl)-N
1
-methylpropane-1,3-diamine 
according to the standard procedure followed by a reductive amination with formaldehyde 
following the procedure of Example 20d step 2. 
1
H NMR (400MHz; CD3OD): δ 1.28 (s, 3H), 1.72 (s, 2H), 2.12 (d, J = 18.0 Hz, 3H), 2.30-
2.40 (m, 2H), 2.63-2.74 (m, 2H), 2.78 (s, 3H), 3.43 (d, J = 20.4 Hz, 2H), 3.84 (s, 2H), 5.08 (s, 
1H), 6.81 (s, 1H), 6.99 (s, 1H), 7.23 (s, 5H), 7.34 (d, J = 7.6 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 
7.59 (s, 1H), 7.99 (s, 1H); m/z (ESI) 627/629 (Cl pattern) [M+H]
+
. 
4-Amino-6-(((S)-1-(6-(3-(((3-((2R,6S)-2,6-
dimethylmorpholino)propyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20j)  
Prepared from aldehyde 16 and 3-((2R,6S)-2,6-dimethylmorpholino)propan-1-amine 
according to the standard procedure followed by a reductive amination with formaldehyde 
following the procedure of Example 20d step 2. 
1
H NMR (300MHz; CD3OD) δ 1.24 (d, J = 6.3 Hz, 6H), 1.31 – 1.53 (m, 3H), 2.15 – 2.37 
(m, 2H), 2.69 (t, J = 11.5, 11.5 Hz, 2H), 2.78 – 2.86 (m, 3H), 2.93 (s, 3H), 3.1 – 3.24 (m, 2H), 
3.24 – 3.31 (m, 2H), 3.41 – 3.56 (m, 2H), 3.8 – 3.98 (m, 2H), 4.34 – 4.54 (m, 2H), 4.99 – 5.25 
(m, 1H), 6.90 (s, 1H), 7.06 (s, 1H), 7.34 – 7.82 (m, 4H), 8.12 (s, 1H); m/z (ESI) 601 [M+H]+. 
(S)-4-amino-6-((1-(6-(3-(((4-
(benzyl(methyl)amino)butyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20k)  
Step 1  
Sodium cyanoborohydride (88 mg, 1.39 mmol) was added in one portion to (S)-4-amino-6-
((1-(6-(3-formylphenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (300 mg, 0.70 mmol), 4,4-diethoxybutan-1-amine 
(337 mg, 2.09 mmol) and AcOH (0.2 mL, 3.48 mmol) in CH2Cl2 (10 mL) and MeOH (10ml) 
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at 25 °C over a period of 15 minutes under nitrogen.  The resulting mixture was stirred at 
25 ºC for 2 hours.  The solvent was removed under reduced pressure and the residue was 
quenched with saturated NaHCO3 (10 mL), extracted with CH2Cl2 (3 x 10 mL), the organic 
layer was dried over Na2SO4, filtered and evaporated to give (S)-4-amino-6-((1-(6-(3-(((4,4-
diethoxybutyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (380 mg, 95 %) as a yellow liquid.  
The product was used in the next step directly without further purification. 
Step 2  
Sodium cyanoborohydride (87 mg, 1.39 mmol) was added in one portion to (S)-4-amino-6-
((1-(6-(3-(((4,4-diethoxybutyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-thiazolo[3,2-
a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (400 mg, 0.69 mmol), formaldehyde (31 
mg, 1.0 mmol) and acetic acid (209 mg, 3.47 mmol) in MeOH (20 mL) at 25 °C over a period 
of 25 minutes under nitrogen. The resulting mixture was stirred at 25 °C for 2 hours. The 
reaction mixture was quenched with saturated NaHCO3 (25 mL) and extracted with EtOAc (3 
x 25 mL).  The organic layer was dried over Na2SO4, filtered and evaporated to give (S)-4-
amino-6-((1-(6-(3-(((4,4-diethoxybutyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (320 mg, 78 %) as a yellow 
oil.  
The product was used in the next step directly without further purification. 
Step 3  
TFA (3.38 mL, 44 mmol) was added portionwise to a cold (0 ºC) solution of (S)-4-amino-6-
((1-(6-(3-(((4,4-diethoxybutyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (400 mg, 0.68 mmol) in 
CHCl3 (40 mL) and H2O (5ml) over a period of 15 minutes. The resulting solution was stirred 
at 25 ºC for 2 hours.  The reaction mixture was quenched with saturated NaHCO3 (25 mL), 
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extracted with CH2Cl2 (3 × 25 mL), the organic layer was dried over Na2SO4, filtered and 
evaporated to give (S)-4-amino-6-((1-(3-methyl-6-(3-((methyl(4-
oxobutyl)amino)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
yl)ethyl)amino)pyrimidine-5-carbonitrile (350 mg, 100 %) as a yellow solid.  
Step 4-(S)-4-amino-6-((1-(6-(3-(((4-
(benzyl(methyl)amino)butyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile 
Sodium cyanoborohydride (24 mg, 0.39 mmol) was added in one portion to (S)-4-amino-6-
((1-(3-methyl-6-(3-((methyl(4-oxobutyl)amino)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-
a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (100 mg, 0.19 mmol), N-methyl-1-
phenylmethanamine (47 mg, 0.39 mmol) and acetic acid (58 mg, 0.97 mmol) in CH2Cl2 (10 
mL) and MeOH (10ml) at 25 °C over a period of 15 minutes under nitrogen.  The resulting 
solution was stirred at 25 ºC for 12 hours. The solvent was removed under reduced pressure.  
The crude product was purified by preparative HPLC (XBridge Prep C18 OBD column, 5µ 
silica, 19 mm diameter, 150 mm length; water (0.5% TFA) and MeCN) to give the title 
compound (89 mg, 62 %) as a yellow solid.  
1
H NMR (300MHz; CD3OD) δ 1.36-1.42 (3H, m), 1.76 - 1.90 (4H, m), 2.73-2.80 (6H, m), 
2.90 (3H, brs), 3.08-3.31 (4H, m), 4.30-4.49 (4H, m), 4.98-5.18 (1H, m), 6.89 (1H, s), 7.07 
(1H, s), 7.45-7.77 (9H, m), 8.05 (1H, s) 4H obscured; m/z (ESI) 621 [M+H]
+
. 
4-Amino-6-(((S)-1-(6-(3-(((4-((2S,6R)-2,6-
dimethylmorpholino)butyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5H-
thiazolo[3,2-a]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (20l)  
Prepared from (S)-4-amino-6-((1-(3-methyl-6-(3-((methyl(4-
oxobutyl)amino)methyl)phenyl)-5-oxo-5H-thiazolo[3,2-a]pyridin-7-
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yl)ethyl)amino)pyrimidine-5-carbonitrile (step 3 20k) and (2S,6R)-2,6-dimethylmorpholine 
under the conditions of step 4 20k. 
1
H NMR (300MHz; CD3OD) δ 1.24 (d, J = 6.3 Hz, 5H), 1.29 – 1.49 (m, 3H), 1.7 – 1.96 (m, 
4H), 2.67 (t, J = 11.5 Hz, 2H), 2.82 (s, 3H), 2.89 (s, 3H), 3.1 – 3.31 (m, 5H), 3.4 – 3.52 (m, 
2H), 3.79 – 3.96 (m, 2H), 4.25 – 4.56 (m, 2H), 4.98 – 5.25 (m, 1H), 6.91 (s, 1H), 7.07 (s, 1H), 
7.38 – 7.82 (m, 4H), 8.09 (s, 1H); m/z (ESI) 615 [M+H]+. 
Enzymatic activity assay for recombinant human PI3Kα, β, δ and γ.  
The activity of recombinant human PI3Kγ ((aa144-1102)-6His) and PI3Kα, β, δ (6-
His(p110– p85α) was determined by measuring the ADP level after phosphorylation of DiC8-
PIP2 using a commercially available ADP-Glo 
TM
 kit from Promega.  The assay was carried 
out in white low volume 384 well plates in a final volume of 14 μl at R.T. The assay 
conditions contained the following: 50 mM Tris buffer pH 7.4, 2.1 mM DTT, 3 mM MgCl2, 
0.05 % CHAPS, 20 μM ATP, 80 μM DiC8-PIP2 and 1.2 nM PI3Kα, β, γ or 0.6 nM PI3Kδ.  
Potential inhibitors were made up in DMSO and then diluted in the assay to give a final 
concentration of not exceeding 1% (v/v) DMSO.  A 10-point half-log dilution series of the 
inhibitors (highest concentration typically 0.1 μM for δ,γ and 33 μM for α, β) was tested and 
the pIC
50
 determined using a 4-paramater logistic equation in a non-linear curve fitting 
routine. Routinely, inhibitors were pre-incubated with 3 μl of enzyme for 15 min prior to the 
addition of 2 μl substrate mixture for a further 60 min enzyme reaction.  The phosphorylation 
was stopped with the addition of 3 μl ADP-GloTM reagent (stop solution) followed by a 40 
min incubation. Prior to detection 6 μl of ADP-GloTM Kinase Detection Reagent was added 
and the plates were read in a micro plate reader using a Luminescence filter. All additions 
were followed by a short centrifugation step. 
Inhibition of cellular activity in JeKo-1 cells. 
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PI3Kδ inhibitors were identified by measuring the phosphorylation of AKT (at Ser473) 
using TR-FRET technology (Phospho-AKT (Ser473) kit, Cisbio) in JeKo-1 cells - 
Lymphoblast B cell line (ATCC).  Cryogenically preserved cells were thawed rapidly in 
RPMI 1640 medium (10 % FBS, 2 mM Glutamine) at 37 °C.  Cells were plated in white low 
volume 384 well plates at a density of 1.25E6 cells/ml in assay buffer (RPMI 1640 medium, 2 
mM Glutamine).  Potential inhibitors were made up in DMSO and then diluted in the assay to 
give a final concentration of not exceeding 1% (v/v) DMSO.  A 10-point half-log dilution 
series of the inhibitors (highest concentration typically 1 μM) was tested and the pIC
50
 
determined using a 4-paramater logistic equation in a non-linear curve fitting routine.  
Inhibitors were incubated with 8 μl of cells for 60 min at 30 °C previously stimulated with 2 
µl Anti-IgM (250 ng/ml) in assay buffer.  After an incubation of 10 min at 37 °C the cells 
were lysed for 30 min at RT on a plate shaker at 500 rpm.  A 5 µl mix of d2/cryptate was 
added to the plates and the FRET signals were read in a micro plate reader after 3-4 h at 620 
nm & 665 nm. 
Rat intratracheal instillation to determine the lung retention of inhaled compounds  
All rat experiments were approved by the Gothenburg Ethics Committee for Experimental 
Animals in Sweden and conform to Directive 2010/63/EU, ethical license No. 135-2014 
The lung half-lives and percentage remaining in the lung at 4 h of the compounds were 
determined after intratracheal instillation as previously described.
34
  The terminal phase of the 
time-concentration curve was used for determination of the half-lives. Briefly, a special 
cannula, connected to a syringe, was inserted in the trachea at the first bifurcation and 0.5 
mL/kg was instilled into the trachea. Sampling of lungs were made at predefined time-points, 
and the lungs were placed on ice and stored at - 20 
o
C until homogenization (Bertin 
technologies) prior to analysis with LC-MS/MS. 
Target engagement in vivo model 
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All mouse experiments were approved by the Gothenburg Ethics Committee for 
Experimental Animals in Sweden and conform to Directive 2010/63/EU, ethical license No. 
47-2013 
The T-cell receptor transgenic mouse (OT-II; C57BL/6-Tg(TcraTcrb)425Cbn/Crl
28
 was 
ordered (Charles River, Sulzfeld, Germany) as 8-10 weeks of age, randomized upon arrival, 
and allowed to acclimatise at least 1 week in the animal facility before the experimental start. 
The mice were OVA (Albumin chicken egg, grade V (Sigma-Aldrich), Sweden, #A5503) 
challenged on day 0 by intranasal administration (50 µg/mouse in 50µL saline) to stimulate 
and recruit inflammatory cells locally to the lung.  Five days later, the lung T-cells were 
activated by the intranasal administration of 0.5 µg anti-CD3 (clone 145-2C11, Cat# 553057 
from BD Bioscience) per mouse in 50µL saline.  Isotype Hamster IgG1 (clone A19-3 Cat# 
553968 from BD Bioscience) was used as control. The animals were (2.5 mL/kg Bw) treated 
intratracheally with PI3Kδ inhibitor (or vehicle for control animals) 18 hours prior to anti-
CD3 challenge.  The bronchoalveolar lung lavage (BAL) cells were isolated 6 hours after 
anti-CD3 challenge, fixed by Phosflow Fix buffer I and permeabilised by permeabilisation 
buffer III (both from BD Bioscience).  Cells were then stained with phospho-S6 Ribosomal 
Protein (Ser235/236) (D57.2.2E) XP®Rabbit mAb (AlexaFluor488 Conjugate, Cell Signaling 
Technology) and data were collected using a LSRFortessa cell analyser (BD Biosciences).  
Data analysis was performed using FlowJo (Tree Star) software. 
 
Supporting Information 
Ligand diagrams for the crystal structures; Kinase selectivity profile for 20b & 20f; 
Analytical HPLC conditions; HPLCMS results; Synthesis procedures for compounds 1 & 2; 
NMR spectra for compounds 3–20l; HPLCMS traces for compounds 20b & 20f 
This material is available free of charge via the Internet at http://pubs.acs.org 
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13, 15a-g  
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15c, 17-19  
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20a-l  
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Compound 13 bound in murine PI3Kd showing the ATP binding pocket with the induced pocket between 
Trp760 and Met752 and with hydrogen bonds to the NH of Val828 and the carbonyl of Glu826 making the 
hinge interaction.  
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View of 15c (grey) overlayed with 13 (blue) showing the very similar conformations adopted by the ligands 
and the almost identical protein conformations.  Note the movement of the sidechain amide of Asn836 
permitting the dimethylamino group to be accommodated.  
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Docked structure of 20f (grey) overlaid with 13 (blue) in murine PI3K showing the large substituted 
aminopiperidine accommodated in the solvent channel.  
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Enzyme and cell potencies for compounds 13, 15a-g, 17, 18, 19 showing cell drop-off at low lipophilicity.  
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Rat ITPK time-course profiles of selected examples.  
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Relationships between lung retention (% remaining at 24 h; half-life) and the first and second pKas or 
Lipophilicity (LogD) for dibases 20a-l.  
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Cell drop-off for dibases.  
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Inhibition of pS6RP in lung lavage after anti-CD3 challenge to OTII mice. 9a compound 20b  9b compound 
20f.  Target engagement of PI3Kδ activity is shown through measurements of pS6RP in bronchoalveolar 
lung lavage cells after anti-CD3 challenge to OVA-challenged OTII mice.  Phosphorylation of S6RP, measured 
using phosphospecific antibodies, was significantly inhibited by both 20b (9a) and 20f (9b) in a dose-
dependent manner, however the inhibition by 20b showed better potency.  Data is shown as results for 
individual animals at each dose with the statistical significance indicated as follows above the columns : 
p<0,001 ***; p<0,005 **; p<0,05 *  
 
177x96mm (100 x 100 DPI)  
 
 
Page 69 of 69
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
R 
    
PI3Kδ enzyme pIC
50
 9.4 9.3 9.3 9.2 
PI3Kδ cell pIC
50
 9.1 8.8 8.0 8.9 
Lung t½ (h) <0.1< 2.3 23.2 9.9 
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